Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111522373 | 11152237 | 3 | F | 20150304 | 20160825 | 20150601 | 20160830 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-033852 | BRISTOL MYERS SQUIBB | 83.92 | YR | M | Y | 51.00000 | KG | 20160830 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111522373 | 11152237 | 1 | SS | APIXABAN | APIXABAN | 1 | Oral | 2.5 MG, BID | 0 | 2.5 | MG | BID | |||||||
| 111522373 | 11152237 | 2 | PS | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Unknown | 0.75 MG, QD | 9218 | .75 | MG | QD | |||||||
| 111522373 | 11152237 | 3 | C | DIGOXIN. | DIGOXIN | 1 | Oral | 0.125 MG, QD | U | 0 | .125 | MG | QD | ||||||
| 111522373 | 11152237 | 4 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 111522373 | 11152237 | 5 | C | BLOPRESS | CANDESARTAN CILEXETIL | 1 | Oral | 12 MG, QD | U | 0 | 12 | MG | QD | ||||||
| 111522373 | 11152237 | 6 | C | FLUITRAN | TRICHLORMETHIAZIDE | 1 | Oral | 1 MG, QD | U | 0 | 1 | MG | QD | ||||||
| 111522373 | 11152237 | 7 | C | MAINTAIN | 2 | Oral | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | |||||||
| 111522373 | 11152237 | 8 | C | LIPIDIL | FENOFIBRATE | 1 | Oral | 80 MG, QD | U | 0 | 80 | MG | QD | ||||||
| 111522373 | 11152237 | 9 | C | BUP-4 | PROPIVERINE | 1 | Oral | 20 MG, QD | U | 0 | 20 | MG | QD | ||||||
| 111522373 | 11152237 | 10 | C | AVOLVE | DUTASTERIDE | 1 | Oral | 0.5 MG, QD | U | 0 | .5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111522373 | 11152237 | 1 | Thrombosis prophylaxis |
| 111522373 | 11152237 | 2 | Product used for unknown indication |
| 111522373 | 11152237 | 3 | Product used for unknown indication |
| 111522373 | 11152237 | 4 | Hypertension |
| 111522373 | 11152237 | 5 | Hypertension |
| 111522373 | 11152237 | 6 | Hypertension |
| 111522373 | 11152237 | 7 | Product used for unknown indication |
| 111522373 | 11152237 | 8 | Dyslipidaemia |
| 111522373 | 11152237 | 9 | Pollakiuria |
| 111522373 | 11152237 | 10 | Benign prostatic hyperplasia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111522373 | 11152237 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111522373 | 11152237 | Contraindicated product administered | |
| 111522373 | 11152237 | Pneumonia aspiration |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111522373 | 11152237 | 1 | 20140405 | 0 | ||
| 111522373 | 11152237 | 2 | 20140404 | 0 | ||
| 111522373 | 11152237 | 8 | 20150303 | 0 |